CGNH — CardioGenics Holdings Share Price
Last trade - 00:00- $0.00m
- $0.38m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Oct | Unit | 2011 | 2012 | 2013 | 2014 | 2015 | 2016E | 2017E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.01 | 0 | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CardioGenics Holdings Inc. is focused on technology and products targeting the immunoassay segment of the In-Vitro Diagnostic testing market. The Company has developed the QL Care Analyzer, a point-of-care immuno-analyzer, which is capable of running approximately 200+immunoassay diagnostic tests, such as cardiovascular diagnostic tests. As part of its technology, the Company has also developed a method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improves instrument sensitivity to light.
Directors
- J. Tabatznik CHM (66)
- Yahia Gawad CEO (58)
- James Essex CFO (68)
- Linda Sterling SEC (55)
- Karim Murabet IND (58)
- Last Annual
- October 31st, 2015
- Last Interim
- January 31st, 2016
- Incorporated
- December 16th, 1997
- Public Since
- June 9th, 2004
- No. of Employees
- 7
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 96,050,558
- Address
- 6865 SW 18th St Ste B13, BOCA RATON, 33433-7057
- Web
- http://www.cardiogenics.com/
- Phone
- +1 9056738501
- Auditors
- CohnReznick LLP
Similar to CGNH
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
As of Today at 24:19 UTC, shares in CardioGenics Holdings are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in CardioGenics Holdings last closed at $0.00 and the price had moved by -99% over the past 365 days. In terms of relative price strength the CardioGenics Holdings share price has underperformed the S&P500 Index by -99.16% over the past year.
There is no consensus recommendation for this security.
CardioGenics Holdings does not currently pay a dividend.
CardioGenics Holdings does not currently pay a dividend.
CardioGenics Holdings does not currently pay a dividend.
To buy shares in CardioGenics Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in CardioGenics Holdings had a market capitalisation of $0.00m.
Here are the trading details for CardioGenics Holdings:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CGNH
Based on an overall assessment of its quality, value and momentum CardioGenics Holdings is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CardioGenics Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -9.44%.
As of the last closing price of $0.00, shares in CardioGenics Holdings were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The CardioGenics Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
CardioGenics Holdings' management team is headed by:
- J. Tabatznik - CHM
- Yahia Gawad - CEO
- James Essex - CFO
- Linda Sterling - SEC
- Karim Murabet - IND